Appointment

e-therapeutics plc shares now trading on JP Jenkins

Retrieved on: 
fredag, maj 10, 2024
RNA interference, Commercial, AIM, ETX, Galapagos NV, Automation, Appointment, Novo Nordisk, Companies House, Biology, Drug development, Drug discovery, Therapy, MASH, Pharmaceutical industry

JP Jenkins provides a share trading venue for unlisted or unquoted assets in companies, enabling shareholders and prospective investors to buy and sell equity on a matched bargain basis.

Key Points: 
  • JP Jenkins provides a share trading venue for unlisted or unquoted assets in companies, enabling shareholders and prospective investors to buy and sell equity on a matched bargain basis.
  • JP Jenkins is a trading name of InfinitX Limited and Appointed Representative of Prosper Capital LLP (FRN453007).
  • The indicative pricing for the ordinary shares (ISIN: GB00B2823H99), as well as the transaction history, will be available on the JP Jenkins website at (https://jpjenkins.com/company/e-therapeutics-plc/).
  • Veronika Oswald, Commercial Director of JP Jenkins said: “ETX’s transition from AIM to the JP Jenkins venue marks a pivotal milestone in our mission to enhance accessibility and liquidity for their shareholders and investors.

Loopup Group plc shares now trading on JP Jenkins

Retrieved on: 
fredag, maj 3, 2024
Commercial, AIM, Microsoft Teams, LOOP, Appointment, Companies House, Security (finance)

11th April 2024 – Shares in Loopup Group plc ( https://loopup.com/ ) have been admitted to trade on JP Jenkins share dealing platform.

Key Points: 
  • 11th April 2024 – Shares in Loopup Group plc ( https://loopup.com/ ) have been admitted to trade on JP Jenkins share dealing platform.
  • JP Jenkins provides a share trading venue for unlisted or unquoted assets in companies, enabling shareholders and prospective investors to buy and sell equity on a matched bargain basis.
  • JP Jenkins is a trading name of InfinitX Limited and Appointed Representative of Prosper Capital LLP (FRN453007).
  • The indicative pricing for the ordinary shares (ISIN: GB00BYQP6S60), as well as the transaction history, will be available on the JP Jenkins website at (https://jpjenkins.com/company/loopup/)
    Veronika Oswald, Commercial Director of JP Jenkins said: “We welcome LoopUp and its directors to JP Jenkins.

BioHive Announces BioHive Live

Retrieved on: 
torsdag, april 18, 2024
Innovation, Doctor of Philosophy, Recursion, University, Appointment, Movement, ALS, Creativity

Salt Lake City, April 18, 2024 (GLOBE NEWSWIRE) -- Today, BioHive announced the launch of BioHive Live , a new event for Utah’s robust life sciences and health innovation community.

Key Points: 
  • Salt Lake City, April 18, 2024 (GLOBE NEWSWIRE) -- Today, BioHive announced the launch of BioHive Live , a new event for Utah’s robust life sciences and health innovation community.
  • "BioHive Live is not just a conference; it's a movement.
  • It's about fostering collaboration, driving innovation, and propelling Utah to the forefront of the global life science stage,” said Aimee Edwards, Executive Director of BioHive.
  • BioHive Live promises to inspire, educate and connect professionals across the industry spectrum.

Ocular Therapeutix™ Strengthens Clinical Team with Appointment of Key Retinal Leaders

Retrieved on: 
tisdag, april 16, 2024
Retina, AMD, FDA, CMO, CDO, Diabetic retinopathy, Doctor of Philosophy, OD, Appointment, Patient, MPH, CSO, Health, Diabetes, Clinical trial, Quality of life, Retinal, Nursing

BEDFORD, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) (“Ocular”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other diseases and conditions of the eye, today announced that it has strengthened its clinical development organization with the appointment of Nadia K. Waheed, MD, MPH, as Chief Medical Officer (CMO); Peter K. Kaiser, MD as Chief Development Officer (CDO); Andrea Gibson, Ph.D., as Vice President, Medical Collaborations; and Namrata Saroj, OD, as Development Strategy Consultant. Dr. Waheed’s appointment will be effective as of May 20, 2024. Jeffrey S. Heier, MD, will continue in his role as Chief Scientific Officer (CSO).

Key Points: 
  • “I am thrilled to announce the enrichment of Ocular’s clinical development organization with the appointment of four recognized retinal disease professionals.
  • Having a strong team of retinal leaders with experience across all aspects of clinical development is essential to Ocular’s transformation to becoming a leading retina company,” said
    Pravin U. Dugel, MD, Executive Chairman, President and Chief Executive Officer of Ocular Therapeutix.
  • In addition, I believe our strengthened clinical team also puts Ocular in an excellent position to accelerate expansion into retinal indications beyond wet AMD, including diabetic retinopathy.”
    Dr. Waheed said, “I am honored to be part of the Ocular Therapeutix team.
  • I joined Ocular because I believed that AXPAXLI could be a ‘game-changer’ in the care of retinal disease.

CafeDirect PLC Shares now trading on JP Jenkins

Retrieved on: 
onsdag, april 10, 2024
Farmer, Appointment, Cafédirect, Coffee, Commercial, NEWS, Companies House, Security (finance)

10th April 2024 – Shares in Cafedirect PLC ( https://www.cafedirect.co.uk/ ) have been admitted to trade on JP Jenkins share dealing platform.

Key Points: 
  • 10th April 2024 – Shares in Cafedirect PLC ( https://www.cafedirect.co.uk/ ) have been admitted to trade on JP Jenkins share dealing platform.
  • Cafedirect plc is a British coffee company established in 1991 that is driven by a passion for fairness and sustainability.
  • JP Jenkins is a trading name of InfinitX Limited and Appointed Representative of Prosper Capital LLP (FRN453007).
  • Veronika Oswald, Commercial Director of JP Jenkins said: “Congratulations to CafeDirect PLC for joining our securities trading venue.

Allarity Therapeutics Reports Full Year 2023 Financial Results and Provides a Business Update

Retrieved on: 
fredag, mars 8, 2024
Eli Lilly, Therapy, Research, Enzyme, CDX, PARP, Drug development, DRP, ADP, Interim, Biomarker, Ovarian cancer, Administration, Patient, Oncology, G&A, Appointment, Cancer, Pharmaceutical industry

The Company's Interim Chief Executive Officer, Thomas Jensen, stated, “2023 was a year of remarkable achievements for Allarity Therapeutics as we made significant strides in advancing our DRP®-guided drug development.

Key Points: 
  • The Company's Interim Chief Executive Officer, Thomas Jensen, stated, “2023 was a year of remarkable achievements for Allarity Therapeutics as we made significant strides in advancing our DRP®-guided drug development.
  • Announced leadership changes and strategic advisory engagement:
    Appointment of co-founder Thomas H. Jensen as Interim Chief Executive Officer in December 2023.
  • With nearly two decades at Allarity Therapeutics, Jensen brings extensive experience and a deep understanding of the company’s DRP® to his new role.
  • Net Loss from Operations: Net Loss from Operations was $17.1 million for 2023, compared to $34 million for 2022.

Tintra Limited Shares now trading at JP Jenkins

Retrieved on: 
måndag, februari 5, 2024
Appointment, 2nd Floor, Companies House, Artificial intelligence, Security (finance)

1st February 2024 – Shares in Tintra Limited (https://tintra.com/) have been admitted to trade on JP Jenkins share dealing platform.

Key Points: 
  • 1st February 2024 – Shares in Tintra Limited (https://tintra.com/) have been admitted to trade on JP Jenkins share dealing platform.
  • Tintra Limited has recently left LSE:AIM and joined JP Jenkins to support a wider investor audience.
  • JP Jenkins is a trading name of InfinitX Limited and Appointed Representative of Prosper Capital LLP (FRN453007).
  • Data for the ordinary shares (ISIN: GB00BHXM9D70), as well as the transaction history, will be available on the JP Jenkins website at (https://jpjenkins.com/company/tintra/)

Zentalis Pharmaceuticals Strengthens Management Team with Key Appointments

Retrieved on: 
torsdag, januari 25, 2024
Citadel, Portfolio manager, Neoplasm, Pharming, T. Rowe Price, Biology, Research, Health care, SAN, Medical school, Science, Princeton University, University, Pharmacology, Denison University, Cancer, Medication, Biomedical sciences, WEE1, Drug development, Therapy, Ovarian cancer, Doctor of Philosophy, Eventide, Appointment, Cowen Inc.

NEW YORK and SAN DIEGO, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancer, today announced that Diana Hausman, M.D., a member of Zentalis’ Board of Directors, was appointed as Chief Medical Officer, and Kyle Rasbach, Ph.D., Pharm.D., was appointed as Chief Business Officer.

Key Points: 
  • “We are pleased to welcome Diana and Kyle to our management team.
  • During her career, she has contributed to the development of multiple cancer therapeutics, including small molecules, antibody drug conjugates, and immunotherapies.
  • In connection with her appointment as Chief Medical Officer, Dr. Hausman resigned from Zentalis’ Board of Directors.
  • Dr. Brownstein will remain with Zentalis as a consultant for a transitional period.

Newmont Strengthens Leadership Team with Appointment of Industry Leader Peter Wexler as Chief Legal Officer

Retrieved on: 
onsdag, januari 24, 2024
Mining, Minerals, Natural Resources, ASX, University, American University, NGT, Peter, Multimedia, Corporation, Financial Times, Law, APC by Schneider Electric, Risk, M&A, Gold, NEM, TSX, Schneider Electric, Risk management, Washington College of Law, Appointment, Engineering, Negotiation, Management

Newmont Corporation (NYSE: NEM, TSX: NGT, ASX: NEM, PNGX: NEM) today announced the appointment of Peter Wexler as Chief Legal Officer.

Key Points: 
  • Newmont Corporation (NYSE: NEM, TSX: NGT, ASX: NEM, PNGX: NEM) today announced the appointment of Peter Wexler as Chief Legal Officer.
  • Peter will join Newmont’s Executive Leadership Team and be responsible for leading the company’s legal, compliance and regulatory affairs globally.
  • View the full release here: https://www.businesswire.com/news/home/20240123636145/en/
    Newmont Strengthens Leadership Team with Appointment of Industry Leader Peter Wexler as Chief Legal Officer (Photo: Business Wire)
    Peter is an experienced legal and risk management leader with more than three decades of international knowledge in managing legal, risk, compliance, M&A, antitrust, litigation and corporate governance affairs within the industrial, technology, energy management, engineering, manufacturing, and construction sectors.
  • As Schneider Electric’s Chief Legal Officer, Peter managed the company’s legal, risk management and compliance matters across the globe and directed a team of over 300 professionals in 32 countries.

ADVANO Appoints J. Christopher York as Chief Executive Officer to Lead the Transition to an Application Oriented Enterprise Advancing Silicon-Carbon Composite Battery Materials

Retrieved on: 
torsdag, januari 11, 2024
Lithium, EVS, Rail transport by country, Research, Growth, City, Partnership, Business development, Strategic planning, Appointment, SPP, EV, Commercialization, Inflation, Management

NEW ORLEANS, Jan. 11, 2024 /PRNewswire/ -- ADVANO, a silicon solutions provider, is accelerating the commercialization of its proprietary silicon anode "drop-in" technology, REALSi™. The transition to an application-oriented enterprise has been made possible with the new leadership of J. Christopher York and further advancements in ADVANO's silicon-carbon composite battery materials.

Key Points: 
  • The transition to an application-oriented enterprise has been made possible with the new leadership of J. Christopher York and further advancements in ADVANO's silicon-carbon composite battery materials.
  • ADVANO has engaged in significant product development efforts yielding a cost-effective, high-performance silicon-carbon composite material for energy storage.
  • Silicon is a critical material that will assume a leading role in the ongoing energy transition," said Christopher York.
  • Prior to joining ADVANO, Christopher held executive leadership positions for over two decades at distinguished companies, including NOVONIX and ELKEM.